Form D · Biotechnology
Bilayer Therapeutics, Inc.
Cambridge, MA · CIK 0001859506
Offering snapshot reported Aug 4, 2023 · SEC filing
- Reported sold
- $300K Offering amount: $1M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 3, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 4, 2023 | Initial | $300,000 | No comparison | 1 | SEC filing |
| Apr 29, 2021 | Initial | $2,000,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-488766
Source: Form D, filed Aug 4, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Thomas A. Collet | Director, Executive |
| Carlo Traverso Giovanni | Director |
| Joshua Korzenik | Director |
| Robert Langer | Director |
| Carlo Giovanni Traverso | Director |
| Huang Yen Chen | Director |
| David Zhu | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One Broadway, 14 Th Floor
Cambridge, MA, 02142
Cambridge, MA, 02142